

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC

Leuven, BELGIË, Boston, MA, VS – 1 december 2023 – 19u00 CET [Oxurion NV](#) (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf dat de volgende generatie zorgstandaard oogheelkundige therapieën ontwikkelt, met klinische activa in vasculaire retinale aandoeningen, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving¹, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving op 22 november 2023 een eerste transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 13 november 2023 0 aandelen van de toen uitstaande 3.112.043.514 aandelen bezat en dus onder de drempel (3%) kwam door de verkoop van stemrechtverlenende effecten. Zie bijlage 1.

Oxurion ontving op 29 november 2023 een tweede transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 17 november 2023 241.545.893 aandelen van de toen uitstaande 3.489.458.972 aandelen bezat en dus boven de drempel (5%) kwam door de verwerving en verkoop van stemrechtverlenende effecten. Zie bijlage 2.

Over Oxurion

Oxurion (Euronext Brussel: OXUR) is een biofarmaceutisch bedrijf met haar hoofdkantoor in Leuven, België, met bedrijfsactiviteiten in Boston, MA. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Voor meer informatie kunt u contact opnemen met:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway "mtconway@conwaycommsir.com"</p>
--	---

1. Artikel 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

BIJLAGE 1

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

13/11/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator


3,112,043,514

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
	# of voting rights	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Holders of voting rights					
Atlas Special Opportunities LLC	232,919,254	0		0.00%	
TOTAL		0	0	0.00%	0.00%


+

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

Sign Envelope ID: F1B079BA-C3D9-4995-8CCF-60F38B4394FF

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Holders of equivalent financial instruments						
TOTAL				0	0.00%	

+

 The totals will be updated once you have clicked on **<CALCULATE>**

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	0	0.00%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 9 November 2023, Atlas Special Opportunities LLC held 157,227,832 shares in Oxurion NV (= 5.05%, with denominator = 3,112,043,514). On 10 November 2023, Atlas Special Opportunities LLC sold 65,678,385 shares in Oxurion NV, as a result of which its shareholding decreased to 91,549,447 shares (= 2.94%, with denominator = 3,112,043,514). On 13 November 2023, Atlas Special Opportunities LLC sold 91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514).

Done at New York

On 17/11/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature RecSigned by
Patrick Vance
35348237820641C

BIJLAGE 2

	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
---	---	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights +

4) Notification by

A person that notifies alone +

5) Persons subject to the notification requirement

Name	Address (for legal entities)

+
+
+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+
+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

17/11/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

5

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

3,489,458,972

 Please enter the denominator before filling in the data


10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Holders of voting rights					
Atlas Special Opportunities LLC	0	241,545,893		6.92%	
TOTAL		241,545,893	0	6.92%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

gn Envelope ID: 7F03E731-92D9-4BC6-8FCE-52174CF89325

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Holders of equivalent financial instruments						
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	241,545,893	6.92%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 15 November 2023, Atlas Special Opportunities LLC purchased 135,869,565 shares in Oxurion NV, as a result of which its shareholding increased to 135,869,565 shares (= 4.18%, with denominator = 3,247,913,079). On 17 November 2023, Atlas Special Opportunities LLC purchased 241,545,893 shares in Oxurion NV, as a result of which its shareholding increased to 377,415,458 shares (= 10.82%, with denominator = 3,489,458,972). On the same day, Atlas Special Opportunities LLC sold 135,869,565 shares in Oxurion NV, as a result of which its shareholding decreased to 241,545,893 shares (= 6.92%, with denominator = 3,489,458,972).

Done at New York

On 24/11/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature 